Navigation Links
Endo Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Leveraged Finance Conference
Date:11/23/2011

CHADDS FORD, Pa., Nov. 23, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that Alan Levin, executive vice president and chief financial officer will present a corporate overview at the Bank of America Merrill Lynch 2011 Leveraged Finance Conference on Thursday, December 1, 2011 at 7:30 a.m. ET.  The conference will be held at the Loews Royal Pacific Resort in Orlando, FL.

A live webcast and audio archive of the presentation will be available on the company's website at http://www.endo.com/.  Click on Investor Relations, and then the link to the Event and Presentation.  Participants should allow approximately ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast.

About Endo

Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company with a diversified business model, operating in three key business segments - branded pharmaceuticals, generics and devices and services. We deliver an innovative suite of complementary products and services to meet the needs of patients in areas such as pain management, pelvic health, urology, endocrinology and oncology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries American Medical Systems, HealthTronics, Inc. and Qualitest Pharmaceuticals, please visit http://www.endo.com/.

    


'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Isis Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Health Care Conference
2. AcelRx Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Health Care Conference
3. Questcor Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference on November 30, 2011
4. Cadence Pharmaceuticals Announces Completion of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters
5. Avanir Pharmaceuticals to Participate in Piper Jaffray Health Care Conference
6. Isis to Receive Up to $14 Million from Pfizer for Its Acquisition of Excaliard Pharmaceuticals
7. Pacira Pharmaceuticals, Inc. Announces Completion of Follow-on Offering of Common Stock and Exercise of Over-Allotment Option
8. Global Markets for Marine-Derived Pharmaceuticals
9. Ferring Pharmaceuticals To Develop Major Corporate Center in Parsippany, New Jersey
10. Omthera Pharmaceuticals, Inc. to Present at the 23rd Annual Piper Jaffray Health Care Conference
11. Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... , April 19, 2017 The Global ... Forecast to 2022 report has covered and analysed the potential ... information on market size, shares and growth factors. The report ... challenges and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major ...
(Date:4/19/2017)... April 19, 2017 ... immune response in pets such as canine, avian ... of various types such as Attenuated Live Vaccines, ... DNA Vaccines and Recombinant Vaccines. Attenuated live vaccines ... or bacteria, which have been weakend under laboratory ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... The National Campaign to Prevent Teen ... to Contraception for Women Servicemembers and Dependents Act of 2017. The bill, introduced ... to ensure that all members of the Armed Forces receive high quality education ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of ... rating of “A” and its outlook as “stable.” At the same time, the ratings ... fallen in recent years, dip below “capital adequacy” thresholds required for its strong rating. ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The ... board members and officers for 2017-2018. The annual board election process has been in ... a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... or hERG liability could substantially improve drug safety and minimize the cost of ... for validating ion channel inhibition using cell lines and for cardiac toxicity using ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... for the North East region. Côté has 20+ years of experience within the ... Phytomer, Côté worked with an array of high-end cosmetic brands, retail brands and ...
Breaking Medicine News(10 mins):